Abstract
Electronic health records (EHRs) are often incomplete and inaccurate, reducing the power of genome-wide association studies (GWAS). Moreover, the variables within these records are often represented in binary codes, masking variation in disease severity among individuals. For some diseases, such as knee osteoarthritis (OA), radiographic assessment is the primary means of diagnosis and can be performed directly from medical images. In this work, we trained a deep learning model (DL-binary) to ascertain knee OA cases from anteroposterior (AP) dual-energy absorptiometry (DXA) scans and achieved clinician level performance. Applying this model across 29,257 individuals from the UK Biobank (UKB), we identified 2,603 (240%) more cases than currently diagnosed in the ICD-10 record. Individuals diagnosed as cases by DL-binary had higher rates of self-reported knee pain, knee pain for longer durations and with increased severity compared to control individuals. We trained another deep learning model to measure the minimum knee joint space width (mJSW), a quantitative phenotype linked to knee OA severity. Despite the DL-binary phenotype and mJSW being highly genetically correlated (92%), the heritability of mJSW was an order of magnitude greater than the ICD-10 code M17 or DL-binary phenotypes. In a GWAS run on mJSW, we identified 18 genome-wide significant loci, as opposed to 1 and 6 at the same sample size using either case-control (DL-binary and ICD-10 code M17) phenotype. This improved power also translated to better polygenic risk score (PRS) prediction for knee OA diagnosis in a holdout dataset of 371,686 individuals. We also show that reduced mJSW, but neither case-control phenotype is associated with increased risk of adult fractures, a leading cause of injury-related death in older individuals. For diseases with radiographic diagnosis, our results demonstrate the enormous potential for using deep learning to phenotype at biobank scale, both for improving power for gene discovery and for epidemiological analysis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
V.M.N was supported on a Good Systems for Ethical AI grant from the University of Texas at Austin. B.F. was supported on an NSF Graduate Research Fellowship DGE 2137420 and DGE 2137420. E.M.J. and B.F were supported by an NIH T32 grant 5T32LMO012414. B.F. was also supported on a UT Austin Provosts Graduate Excellence Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All our data comes from the UKBiobank study. The Ethics Advisory Committee of the UKBiobank gave ethical approval for our work under application ID: 65439.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵+ Co-first authors
Data Availability
All our data comes from the UK Biobank Study under application ID 65439.
